On March 12, 2026, the Clinicaltrial website showed that Smeglutide nasal spray of Shiling Pharmaceutical had registered a phase | clinical study in overweight or obese adult subjects, which was the first clinical trial of the drug.
Semaglutide Powder CAS 910463-68-2
1.We supply
(1)Tablet
(2)Gummies
(3)Capsule
(4)Spray
(5)API(Pure powder)
(6)Pill press machine
https://www.achievechem.com/pill-press
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-2-4-008
Semaglutide CAS 910463-68-2
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
We provide Semaglutide Powder, please refer to the following website for detailed specifications and product information.
Product:https://www.bloomtechz.com/synthetic-chemical/peptide/semaglutide-powder-cas-910463-68-2.html
The study is planned to be conducted in the United States, and 60 people will be included. The purpose is to test the safety, tolerance and pharmacokinetics of Smeagzentide nasal spray in overweight or obese adult subjects compared with placebo and positive control.
The original research of semaglutide was conducted by Novo Nordisk. As a pioneering drug in the GLP-1 field, semaglutide has been popular worldwide since its launch, with a staggering $34.608 billion in 2025. Although it has not yet ascended to the throne of the drug king, it is still a true "money printer".
Smeglutide of Shiling Pharmaceutical is a nasal spray developed based on the mucosal delivery platform. Its advantages lie in: avoiding the first pass effect and improving the bioavailability; Non invasive drug administration, high compliance, more conducive to disease treatment and management; Convenient medication and self administration, it is expected to become the third mainstream dosage form after injections and oral preparations.
Hengrui insulin/GLP-1 compound preparation Shudi insulin Norilside applied for market launch
On March 13, 2026, Hengrui Pharmaceutical received the Notice of Acceptance issued by the State Food and Drug Administration, and the application for marketing of the company's Class 1 innovative drug, long-acting basic insulin analog/glucagon like peptide-1 (GLP-1) receptor agonist fixed compound preparation, Sudirin and Nori Glycopeptide Injection, was accepted. The proposed indications are: applicable to adult type 2 diabetes patients with poor blood sperm control, and combined with other oral hypoglycemic drugs on the basis of diet and exercise to improve blood sugar control.
This application for listing is based on two key phase clinical studies (study numbers: HR17031-301, HR17031-302) of insulin suldi and noriglycopeptide injection (R&D code: HR17031) in adult patients with type 2 diabetes (12DM), which are multi center, randomized, open, and positive drug parallel control. Two studies were conducted to evaluate the efficacy and safety of Shudi insulin and Norilside injection and control drug in T2DM patients with poor blood glucose control treated with oral hypoglycemic agents and basal insulin therapy, respectively.
The HR17031-301 study was led by Professor Ji Linong from Peking University People's Hospital, with a total of 54 centers initiated nationwide and 401 participants randomly enrolled. The HR17031-302 study was led by Professor Chen Liming from Tianjin Medical University Zhu Xianyi Memorial Hospital, with a total of 65 centers initiated nationwide and 393 participants randomly enrolled. The results of the two studies showed that the main endpoint of suldi insulin and noriglycopeptide injection was significantly better than that of the test control group, and the medium and long-term safety and tolerance of suldi insulin and noriglycopeptide injection in patients with type 2 diabetes were good.
Qilu Pharmaceutical's "Oral Simeglutide" Launch Phase Clinical Trial
On March 16, 2026, the drug clinical trial registration and information disclosure platform showed that Qilu Pharmaceutical launched the first phase clinical trial of oral semaglutide biosimilar QLG1091. This study is a multicenter, randomized, double-blind, positive drug controlled clinical trial (n=478), which aims to evaluate the efficacy and safety of GLG1091 compared with oral smectil peptide (English trade name: Rybelsus, Chinese trade name:
Novexin @) in patients with type 2 diabetes who have poor blood glucose control after the treatment of the second middle and double muscles. The main endpoint of the study was the change in glycated hemoglobin (HbA1c) levels from baseline at week 26.
The original research company, Sinovac Biotech, is a GLP-1 receptor (GLP-1 R) agonist developed by Novo Nordisk. Its injectable form Ozempic (Chinese trade name: Novotec) and Wegowy8 (Chinese trade name: Novowy8 @) were approved for market in the United States in December 2017 and June 2021, respectively. The oral form Rybelsus @ was approved for market in the United States in September 2019. According to Novo Nordisk's financial report, in 2025, the three brands of Simegapeptide will generate a total revenue of 34.6 billion US dollars.